ArticlePediatric rheumatology online journal2025
Still's disease: bridging the gap between guidelines and clinical practice.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recently published EULAR/PReS recommendations on Still's disease provide a comprehensive framework for disease classification and management, yet certain aspects warrant further refinement. Defining systemic juvenile idiopathic arthritis (sJIA) as Still's disease underscores the need for updated classification criteria. The routine use of transthoracic echocardiography or thoracic ultrasonography at diagnosis could help detect serosal involvement, aiding in the early identification of interstitial lung disease and cardiac complications. Refining cytopenia definitions by incorporating declining trend of platelet counts despite being within normal ranges may facilitate earlier detection of macrophage activation syndrome (MAS). Additionally, specifying therapeutic target trough levels for cyclosporine A (CsA) in international guidelines would enhance treatment precision. Integrating these insights could improve diagnostic accuracy, facilitate timely interventions, and optimize patient outcomes in Still's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.